STADA, the European pharmaceutical company owned by UK private equity funds Cinven and Bain Capital, has reported revenues of €3 billion alongside double digit growth well ahead of the market.
STADA has a major presence in the UK pharmaceutical and healthcare market with Thornton & Ross (founded in Huddersfield in 1922), a manufacturer of well-known brands such as Covonia, Savlon, Hedrin and Zoflora; Natures Aid, a natural supplements business with a strong export profile; and Britannia, an affiliate bringing innovative treatments for the debilitating illness of Parkinson’s disease.
COVID-19 and Brexit did not stall STADA’s major UK investments. A major multi-million pound investment in STADA’s site at Linthwaite near Huddersfield (over 100 million items are manufactured every year on site) has transformed the site to a STADA centre of excellence for liquids, such as Covonia, household products like Zoflora and semi-solids such as emollient creams and ointments.
The UK business is also leading a US expansion for STADA. UK brands such as Zoflora and Hedrin are increasingly becoming international export brands (Australia, Hong Kong, Serbia and UAE) through STADA’s international marketing and sales infrastructure.
Globally, STADA showed resilience amid the coronavirus pandemic by achieving 18 percent sales and 15 percent adjusted EBITDA growth at constant currencies in 2020. This performance, well ahead of a stagnating market, is testament to the agility and entrepreneurship with which STADA’s diverse global workforce acted under difficult circumstances to keep supplying medicines to patients and healthcare professionals.
“Throughout 2020, ensuring the health and safety of all employees and their families has been STADA’s utmost priority,” said STADA’s CEO Peter Goldschmidt.
“While STADA has responded with agility to the pandemic, we have continued to strengthen our supply-chain infrastructure for a sustainable future. I am proud of how STADA has worked tirelessly with hundreds of partners amid the pandemic to keep supplying medicines and deliver on our purpose of caring for people’s health as a trusted partner.”